NCT02625168View on ClinicalTrials.gov

Afatinib vs Erlotinib as 2nd TKI After Failure to 1st TKI and Chemotherapy for Metastatic NSCLC

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

September 30, 2014

Study Completion Date

December 31, 2014

Conditions
Lung Cancer
Interventions
DRUG

Afatinib

Afatinib from study recruitment until disease progression, intolerable side effects as judged by investigators or patient withdrawal

DRUG

Erlotinib

Erlotinib from study recruitment until disease progression, intolerable side effects as judged by investigators or patient withdrawal

Trial Locations (1)

Unknown

Department of Clinical Oncology, Queen Mary Hospital, Hong Kong

All Listed Sponsors
lead

The University of Hong Kong

OTHER

NCT02625168 - Afatinib vs Erlotinib as 2nd TKI After Failure to 1st TKI and Chemotherapy for Metastatic NSCLC | Biotech Hunter | Biotech Hunter